[Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma]

M L Gershanovich; M E Livshits; V I Antipenkova

[Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma]

Vopr Onkol. 2000;46(5):604-7.

[Article in Russian]

Authors

M L Gershanovich¹, M E Livshits, V I Antipenkova

Affiliation

¹ N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.

PMID: 11202196

Abstract

Combination chemotherapy with hexamethylmelamine (hexalen, altretamine, hexastat), 100 mg, thrice a day, per os, 14 days (out of a 28-day course) and sarcolysin, 15 mg, per os, during the first 5 days of the course, was received by 24 patients with primary advanced tumors of the ovaries, prior to or after cytoreductive surgery. Total apparent response to chemotherapy among 19 patients of the study group was 47.2%, clinically significant (plus stabilization)--94.5%, without significant untoward side-effects (vomiting--19%; leukopenia degree II-III--33% and thrombocytopenia--19%). The drug proved an active component of combination therapy for advanced ovarian carcinoma.

Publication types

English Abstract

MeSH terms

Adult
Aged
Altretamine / administration & dosage
Altretamine / adverse effects
Altretamine / therapeutic use*
Antineoplastic Agents, Alkylating / administration & dosage
Antineoplastic Agents, Alkylating / adverse effects
Antineoplastic Agents, Alkylating / therapeutic use*
Carcinoma / drug therapy*
Carcinoma / secondary
Chemotherapy, Adjuvant
Drug Administration Schedule
Female
Humans
Melphalan / administration & dosage
Melphalan / adverse effects
Melphalan / therapeutic use*
Middle Aged
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / pathology
Retrospective Studies
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Melphalan
Altretamine